secwatch.observer — SEC 8-K summary
======================================

Issuer:     CONMED Corp (CNMD)
CIK:        0000816956
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001193125-24-247545
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CONMED Q3 2024: adj. EPS $1.05 beats; revenue guidance trimmed; CEO transition to Beyer Jan 2025
--------------------------------------------------------------------------------

- Sales $316.7M (+4.0% YoY); GAAP EPS $1.57 (vs $0.50); adjusted EPS $1.05 (+16.7%).
- Full-year revenue guidance lowered to $1.300–1.305B from $1.305–1.315B; adj. EPS raised to $4.00–4.05 from $3.95–4.02.
- COO Pat Beyer appointed President and CEO effective Jan 1, 2025; Curt Hartman will retire and serve as Special Advisor through March 2027.
- Hartman to receive consulting fee of $1.936M plus 2x avg bonus; equity vesting continues through separation date.
- Domestic sales +7.4% YoY; international -0.4%; single-use products +6.9%, capital -10.6%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/816956/000119312524247545/0001193125-24-247545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/816956/000119312524247545/d905685d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-247545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer